Lexicon Pharmaceuticals, Inc. Q2 2009 Earnings Call Transcript
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2009 Earnings Call Transcript July 28, 2009 11:00 AM ETExecutivesJason Ray – Manager, Corporate Communications and ...
Model output · Signal date 2026-10-16
Lexicon Pharmaceuticals, Inc. (LXRX) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Rating · 90D
▲ Bullish
Exact rating locked
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
Top 35%
of 5171 stocks scored
Rank correlation · 90D
44.0%
Spearman, 357 dates
Market Cap
$676M
small-cap · #60 of 60 peers
Summary
Lexicon Pharmaceuticals, Inc. (LXRX) stock forecast summary
Our AI ranks Lexicon Pharmaceuticals, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Lexicon Pharmaceuticals, Inc. is a small-cap company with a market capitalization of $676M. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
For LXRX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 44.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 36.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, LXRX included.
Follow LXRX freePrice
LXRX price chart and AI forecast
Cross-section · 2026-10-16
How LXRX ranks among 5171 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-06-30
Lexicon Pharmaceuticals, Inc. (LXRX) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Valuation & Market
| Metric | LXRX | Rank |
|---|---|---|
| Market Cap | $676M | 60/60 |
| P/B Ratio | 3.88x | 33/42 |
| EPS | $-0.22 | – |
| Book Value/Share | $0.39 | – |
| Revenue/Share | $0.09 | – |
Profitability & Margins
| Metric | LXRX | Rank |
|---|---|---|
| ROE | -35.0% | 28/38 |
| ROA | -24.4% | 33/43 |
| ROIC | -23.2% | 34/46 |
| Operating Margin | -131.4% | 34/39 |
| Net Margin | -147.4% | 31/35 |
| EBT Margin | -129.0% | 41/46 |
Financial Health
| Metric | LXRX | Rank |
|---|---|---|
| Current Ratio | 13.37x | 12/59 |
| Quick Ratio | 13.29x | 2/44 |
| D/E Ratio | 0.43x | 32/48 |
| Financial Leverage | 1.43x | 31/48 |
| Interest Coverage | -23.5x | 30/36 |
| Working Capital | $182M | 51/59 |
Cash Flow
| Metric | LXRX | Rank |
|---|---|---|
| Operating Cash Flow | -$65M | 41/59 |
Operational Efficiency
| Metric | LXRX | Rank |
|---|---|---|
| Asset Turnover | 0.17x | 35/40 |
| Receivables Turnover | 25.2x | 4/38 |
| Inventory Turnover | 0.3x | 35/36 |
| Fixed Assets Turnover | 25.1x | 12/41 |
| Days Sales Outstanding | 14 days | 35/38 |
| Days Inventory | 1219 days | 2/36 |
| Payables Period | 2389 days | 1/26 |
| Cash Conversion Cycle | -1155 days | 24/24 |
Income Statement
| Metric | LXRX | Rank |
|---|---|---|
| Total Revenue | $41M | 45/46 |
| Operating Income | -$54M | 31/51 |
| Net Income | -$61M | 28/46 |
| R&D Expense | $60M | 56/58 |
| SG&A Expense | $35M | 41/41 |
| Cost of Goods Sold | $360K | 37/37 |
Dividend & Shareholder Information
| Metric | LXRX | Rank |
|---|---|---|
| Shares Outstanding | 445M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $197M | 78.6% of assets |
| Cash & Short-term Investments | $41M | 16.4% of assets |
| Accounts Receivable | $2M | 0.7% of assets |
| Inventory | $1M | 0.5% of assets |
| Total Liabilities | $76M | 30.2% of assets |
| Short-term Debt | $12M | 4.9% of assets |
Quarterly Financial Reports
LXRX quarterly financials and insider trading
Industry Peers · Pharmaceutical Preparations
Lexicon Pharmaceuticals, Inc. (LXRX) industry peers
Companies classified under the same SEC industry code as Lexicon Pharmaceuticals, Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| LXRX Lexicon Pharmaceuticals, Inc. | ▲ | $676M |
| LLY Eli Lilly & Co | ▶ | $1.18T |
| JNJ Johnson & Johnson | ▼ | $615.87B |
| ABBV Abbvie Inc. | ▶ | $504.46B |
| MRK Merck & Co., Inc. | ▲ | $360.08B |
| NVS Novartis Ag | ▼ | $287.41B |
| AZN Astrazeneca Plc | ▼ | $256.39B |
| ABT Abbott Laboratories | ▼ | $182.37B |
| NVO Novo Nordisk A S | ▼ | $172.56B |
| PFE Pfizer Inc | ▶ | $168.60B |
| VRTX Vertex Pharmaceuticals Inc / Ma | ▶ | $128.95B |
| BMY Bristol Myers Squibb Co | ▶ | $122.05B |
| GSK Gsk Plc | ▼ | $100.46B |
| SNY Sanofi | ▼ | $100.12B |
| REGN Regeneron Pharmaceuticals, Inc. | ▶ | $81.76B |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $61.45B |
| TEVA Teva Pharmaceutical Industries Ltd | ▼ | $48.36B |
| ONC Beone Medicines Ltd. | ▲ | $41.96B |
| ZTS Zoetis Inc. | ▼ | $32.40B |
| ALNY Alnylam Pharmaceuticals, Inc. | ▶ | $31.02B |
| RPRX Royalty Pharma Plc | ▶ | $26.88B |
| ROIV Roivant Sciences Ltd. | ▲ | $24.22B |
| GMAB Genmab A/S | ▲ | $23.80B |
| UTHR United Therapeutics Corp | ▶ | $23.23B |
| INSM Insmed Inc | ▶ | $21.02B |
| VTRS Viatris Inc | ▼ | $20.93B |
| ASND Ascendis Pharma A/S | ▲ | $14.85B |
| JAZZ Jazz Pharmaceuticals Plc | ▼ | $13.65B |
| BBIO Bridgebio Pharma, Inc. | ▶ | $12.98B |
| CORT Corcept Therapeutics Inc | ▲ | $11.91B |
| ELAN Elanco Animal Health Inc | ▼ | $11.77B |
| SMMT Summit Therapeutics Inc. | ▶ | $11.67B |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.91B |
| BMRN Biomarin Pharmaceutical Inc | ▶ | $10.58B |
| MDGL Madrigal Pharmaceuticals, Inc. | ▶ | $10.39B |
| TGTX Tg Therapeutics, Inc. | ▲ | $8.89B |
| CYTK Cytokinetics Inc | ▲ | $8.61B |
| PTGX Protagonist Therapeutics, Inc | ▶ | $8.33B |
| AXSM Axsome Therapeutics, Inc. | ▲ | $8.23B |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $7.90B |
| ABVX Abivax S.A. | ▼ | $7.74B |
| IONS Ionis Pharmaceuticals Inc | ▲ | $7.14B |
| SYRE Spyre Therapeutics, Inc. | ▲ | $7.05B |
| ALKS Alkermes Plc. | ▲ | $6.92B |
| PRAX Praxis Precision Medicines, Inc. | ▲ | $6.75B |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▶ | $6.13B |
| AMRX Amneal Pharmaceuticals, Inc. | ▲ | $6.13B |
| RYTM Rhythm Pharmaceuticals, Inc. | ▲ | $5.93B |
| LGND Ligand Pharmaceuticals Inc | ▶ | $5.89B |
| BLTE Belite Bio, Inc | ▲ | $5.62B |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.20B |
| COGT Cogent Biosciences, Inc. | ▶ | $5.12B |
| PTCT Ptc Therapeutics, Inc. | ▲ | $4.94B |
| ORKA Oruka Therapeutics, Inc. | ▲ | $4.76B |
| ERAS Erasca, Inc. | ▲ | $4.68B |
| MANE Veradermics, Inc | ▲ | $4.55B |
| TVTX Travere Therapeutics, Inc. | ▲ | $4.44B |
| EWTX Edgewise Therapeutics, Inc. | ▲ | $4.04B |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.03B |
| INDV Indivior Pharmaceuticals, Inc. | ▶ | $3.83B |
Where LXRX sits on the market map
Life Sciences · Pharmaceutical Preparations
News
Lexicon Pharmaceuticals, Inc. (LXRX) stock news
Lexicon Pharmaceuticals, Inc. (LXRX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Welcome to Citi's Biopharma Back-to-school Summit for 2026. We're very pleased to be introducing our next company, Lexicon Pharmaceuticals. We have Mike Exton, CEO. Welcome. Craig Granowitz, CMO; and ...
Is Lexicon Pharmaceuticals, Inc. (LXRX) A Good Stock To Buy Now?
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
FAQ
Lexicon Pharmaceuticals, Inc. (LXRX) stock forecast FAQ
What is the Lexicon Pharmaceuticals, Inc. (LXRX) stock forecast?
Our AI ranks Lexicon Pharmaceuticals, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Lexicon Pharmaceuticals, Inc. stock predictions?
For LXRX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 44.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 36.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Lexicon Pharmaceuticals, Inc. forecasts updated?
Lexicon Pharmaceuticals, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Lexicon Pharmaceuticals, Inc.'s industry peers?
60 issuers in our coverage, LXRX included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.